These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 19858214)
1. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214 [TBL] [Abstract][Full Text] [Related]
2. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites. Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206 [TBL] [Abstract][Full Text] [Related]
3. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019 [TBL] [Abstract][Full Text] [Related]
4. Cdc37-Hsp90 complexes are responsive to nucleotide-induced conformational changes and binding of further cofactors. Gaiser AM; Kretzschmar A; Richter K J Biol Chem; 2010 Dec; 285(52):40921-32. PubMed ID: 20880838 [TBL] [Abstract][Full Text] [Related]
5. The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy. Sreeramulu S; Jonker HR; Langer T; Richter C; Lancaster CR; Schwalbe H J Biol Chem; 2009 Feb; 284(6):3885-96. PubMed ID: 19073599 [TBL] [Abstract][Full Text] [Related]
6. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites. Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315 [TBL] [Abstract][Full Text] [Related]
7. A primate specific extra domain in the molecular chaperone Hsp90. Tripathi V; Obermann WM PLoS One; 2013; 8(8):e71856. PubMed ID: 23951259 [TBL] [Abstract][Full Text] [Related]
8. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties. Jiang F; Wang HJ; Bao QC; Wang L; Jin YH; Zhang Q; Jiang D; You QD; Xu XL Bioorg Med Chem; 2016 Nov; 24(21):5431-5439. PubMed ID: 27647369 [TBL] [Abstract][Full Text] [Related]
9. The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype. Zanphorlin LM; Alves FR; Ramos CH Biochim Biophys Acta; 2014 Oct; 1840(10):3145-52. PubMed ID: 24954307 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity. Li N; Xu M; Wang B; Shi Z; Zhao Z; Tang Y; Wang X; Sun J; Chen L J Med Chem; 2019 Dec; 62(23):10798-10815. PubMed ID: 31725288 [TBL] [Abstract][Full Text] [Related]
11. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex. Stiegler SC; Rübbelke M; Korotkov VS; Weiwad M; John C; Fischer G; Sieber SA; Sattler M; Buchner J J Biol Chem; 2017 Oct; 292(41):17073-17083. PubMed ID: 28851842 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and structural studies of the interaction of Cdc37 with Hsp90. Zhang W; Hirshberg M; McLaughlin SH; Lazar GA; Grossmann JG; Nielsen PR; Sobott F; Robinson CV; Jackson SE; Laue ED J Mol Biol; 2004 Jul; 340(4):891-907. PubMed ID: 15223329 [TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Sreeramulu S; Gande SL; Göbel M; Schwalbe H Angew Chem Int Ed Engl; 2009; 48(32):5853-5. PubMed ID: 19585625 [No Abstract] [Full Text] [Related]
14. Structure of an Hsp90-Cdc37-Cdk4 complex. Vaughan CK; Gohlke U; Sobott F; Good VM; Ali MM; Prodromou C; Robinson CV; Saibil HR; Pearl LH Mol Cell; 2006 Sep; 23(5):697-707. PubMed ID: 16949366 [TBL] [Abstract][Full Text] [Related]
15. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Smith JR; Workman P Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013 [TBL] [Abstract][Full Text] [Related]
16. Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions. Jiang Y; Bernard D; Yu Y; Xie Y; Zhang T; Li Y; Burnett JP; Fu X; Wang S; Sun D J Biol Chem; 2010 Jul; 285(27):21023-36. PubMed ID: 20413594 [TBL] [Abstract][Full Text] [Related]
17. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening. He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254 [TBL] [Abstract][Full Text] [Related]
18. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System. Hallett ST; Pastok MW; Morgan RML; Wittner A; Blundell KLIM; Felletar I; Wedge SR; Prodromou C; Noble MEM; Pearl LH; Endicott JA Cell Rep; 2017 Oct; 21(5):1386-1398. PubMed ID: 29091774 [TBL] [Abstract][Full Text] [Related]
19. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. Siligardi G; Panaretou B; Meyer P; Singh S; Woolfson DN; Piper PW; Pearl LH; Prodromou C J Biol Chem; 2002 Jun; 277(23):20151-9. PubMed ID: 11916974 [TBL] [Abstract][Full Text] [Related]
20. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]